Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Altimmune (NASDAQ:ALT) in the last three months.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 1 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 1 | 0 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for Altimmune, presenting an average target of $19.25, a high estimate of $25.00, and a low estimate of $12.00. Consistency is reflected as the current average remains at the same level as the previous average price target.
Breaking Down Analyst Ratings: A Detailed Examination
The perception of Altimmune...
Login or create a forever free account to read this news
Sign up/Log in